Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy

NCT00055601 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT00055601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2002
Completion date
May 14, 2018
Enrollment
97 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer